Repare Therapeutics stock is down as insiders flock to buy the $30-million RPTX dipFinbold • 06/13/22
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare ConferenceBusiness Wire • 06/07/22
Repare Therapeutics shares rise by 25% after it announced its collaboration deal with RocheInvezz • 06/04/22
Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billionMarket Watch • 06/02/22
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)Business Wire • 06/01/22
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality DayBusiness Wire • 05/09/22
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial ResultsBusiness Wire • 05/05/22
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 AmplificationBusiness Wire • 04/20/22
Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?Zacks Investment Research • 04/13/22
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual MeetingBusiness Wire • 04/11/22
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual MeetingBusiness Wire • 04/08/22
Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual MeetingBusiness Wire • 03/08/22
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies CongressBusiness Wire • 03/07/22
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 03/01/22
Repare Therapeutics to Participate in Two Upcoming Virtual Investor ConferencesBusiness Wire • 02/03/22
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022Business Wire • 01/07/22
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product DevelopmentBusiness Wire • 01/05/22
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/22
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid TumorsBusiness Wire • 12/21/21